AbstractThe incidence of Oesophageal Adenocarcinoma (OAC) has risen six-fold in the western world in the last forty years but response rates to chemotherapy are low and survival is poor. Increased molecular understanding of this heterogeneous disease is needed to overcome resistance to chemotherapy and develop novel therapeutic strategies. This study uses gene expression data to perform unbiased molecular subtyping followed by functional genomic screening to identify novel drug targets to improve outcomes in OAC.
Thesis embargoed until 31 July 2023.
|Date of Award||Jul 2021|
|Supervisor||Richard Turkington (Supervisor) & Richard Kennedy (Supervisor)|